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Abstract As serum amyloid A (SAA), an apolipoprotein 
associated with HDL during the acute-phase reaction may 
induce Ca2+ mobilization in human monocytes we raised the 
question whether SAAX the predominant isoform of human acute-
phase SAA is able to alter eicosanoid formation. In resting 
monocytes SAA] was without effect on the secretion of 
cyclooxygenase metabolites while in calcium ionophore A23187-
(0.5 and 2.5 uM) stimulated cells SAAt led to a pronounced 
dose-dependent increase of TXA2, PGE2, and PGF2ct. In 
addition a time-dependent increase of cyclooxygenase metabo-
lites in between 1.5- and 3-fold in the presence of SAA] was 
observed; apo A-I, the main HDL-apolipoprotein under non-
acute-phase conditions, had no effect. Using sequence-specific 
anti-human SAAt peptide (40-63) F(ab)2 fragments we could 
show that the proposed Ca2+-binding tetrapeptide Gly48-Pro49-
Gly50-Gly51 of SAA] is not responsible for enhanced biosynthesis 
of cyclooxygenase metabolites. Finally, we could demonstrate 
that human SAAx is unable to bind Ca2+-ions, suggesting that 
SAA] does not directly enhance eicosanoid biosynthesis via Ca2+ 
mobilization leading to enhanced phospholipase A2 activity. 
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1. Introduction 
Mammalian liver responds to various systemic injuries, 
such as acute inflammation, infection, or burns with profound 
changes in plasma concentrations of a group of proteins, 
termed acute-phase proteins [1]. In humans serum amyloid 
A (SAA) protein is expressed during the acute-phase reaction 
in response to cytokines released by activated monocytes/mac-
rophages. SAA may reach plasma levels up to 1000-fold great-
er than that found in the non-inflammatory state (2-5 u,g/ml), 
thus representing an ideal marker for clinical use [2,3]. Serum 
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levels of SAA are increased during bacterial and viral infec-
tions and a number of chronic inflammatory and neoplastic 
diseases which may predispose to amyloidosis [3]. In amyloi-
dosis, SAA (104 amino acids, 12 kDa) is usually processed by 
cleavage between residues 76 and 77, and the N-terminal res-
idue, the amyloid A protein, is incorporated into the bulk of 
fibrils in secondary reactive amyloidosis [4]. 
Upon release into the circulation SAA is mainly complexed 
with lipoproteins of the high density range [5] by displacing 
apolipoprotein A-I (apo A-I) the major protein component of 
native high density lipoproteins (HDL) [6]. While remodeling 
its physiological carrier during the acute-phase reaction, SAA 
may significantly impede the protective function of HDL in 
reverse cholesterol transport in humans [7]. Displacement of 
HDL-associated apo A-I by SAA was demonstrated to reduce 
the binding properties of SAA-enriched HDL to hepatocytes 
which was accompanied with a 3- to 4-fold higher binding 
affinity to macrophages resulting in a significant shift in 
HDL-cholesterol carrying capacity towards the macrophage 
[8]. 
Besides its principal role as acute-phase protein, amyloide-
genic protein, and apolipoprotein, some specific functions 
have been proposed for SAA. Among these are anti-tumor 
growth properties [9], platelet activation [10], inhibition of 
lymphocyte antibody response [11], induction of T-lympho-
cyte migration and adhesion [12], directional migration of 
monocytes and polymorphonuclear leukocytes as well as ex-
pression of adhesion proteins and adhesion molecules [13]. 
Recent results suggested that recombinant SAA (rSAA) may 
be effective in chemoattracting monocytes resulting in transi-
ent elevation of cytoplasmic Ca2+ concentrations [14] and that 
SAA might even enhance the activity of secretory non-pan-
creatic phospholipase A2 (PLA2) [15]. 
After activation the PLA2 hydrolyses the glyceryl-fatty-acid 
ester bond at the sn-2 position of phospholipid molecules 
where arachidonic acid (AA) is most frequently found. AA 
is the precursor to a broad array of structurally diverse and 
potent bioactive lipids that include prostaglandins, thrombox-
anes, leukotrienes, lipoxins, as well as other oxygenated fatty 
acids [16,17]; collectively, these molecules are termed eicosa-
noids. In human tissues, prostaglandins and thromboxanes, 
both cyclooxygenase metabolites, are potent mediators of in-
flammation involved in the regulation of platelet-vessel wall 
interactions and in the regulation of blood vessel tone and 
hemostasis [18]. The fact that SAA contains a highly con-
served tetrapeptide Gly48-Pro49-Glyo0-Gly51 a sequence ho-
mologous to Gly30-Xaa31-Gly32-Gly33, the main Ca2+- and 
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lipid-binding site in PLA 2 molecules [19,20], suggested that 
properties of altered eicosanoid balance in resting or activated 
cells might be due to the proposed Ca2 +-sensitive epitope 
present in SAA. 
As SAA contributes to enhanced migration of monocytes 
and polymorphonuclear leukocytes to inflamed tissues [13] 
and the fact that both SAA and secretory PLA 2 are rapidly 
induced during inflammatory events [15], the present study 
was aimed at investigating whether SAA might alter the se-
cretion of biologically active AA-metabolites, i.e. TXA2, 
PGE2, and PGF2a. As in humans the predominant SAA iso-
form is SAAi ( > 95% of total SAA); all experiments were 
performed with this protein. 
2. Materials and methods 
2.1. Isolation and purification of apolipoproteins 
Crude SAAi was prepared directly from human plasma (obtained 
from patients with rheumatoid arthritis or patients undergoing plas-
mapheresis for therapeutic purposes) by hydrophobic interaction 
chromatography on Octylsepharose CL 4B followed by gel permea-
tion-fast protein liquid chromatography on Superdex 75 prep grade as 
described [21]. Subsequently SAAi was purified from remaining SAA 
isoforms and other apolipoproteins (apo A-I, apo A-II, and apo Cms) 
by preparative IEF using the Rotofor system (Bio-Rad) and buffers 
containing 6 M urea, 10% (w/v) glycerol and 6.4% (w/v) carrier am-
pholytes [21]. Non-acute-phase HDL subclass 3 (d = 1.125-1.21 g/ml), 
isolated by density gradient ultracentrifugation, was incubated with 
6 M guanidine/HCl for 3 h at 37°C. After recentrifugation at a density 
of 1.21 g/ml, apo A-I was isolated from the lipid-free bottom fraction 
by gel permeation chromatography as described above. Aliquots of 
SAAi and apo A-I tested were negative for endotoxin in Limulus 
amebocyte lysate (BioWhittaker, sensitivity 0.06 EU/ml). 
2.2. Preparation of sequence-specific F ( ab )% fragments 
Sequence-specific antibodies to humans SAAi were raised in rabbits 
using Freud's complete adjuvant (Sigma). The immunogen was a syn-
thetic peptide (corresponding to amino acid residues 40-63 of human 
SAAi) coupled via its C-terminal residue to JV-maleimido-butyryl-JV-
hydroxysuccinimide ester-activated keyhole-limpet haemocyanin [22]. 
To obtain F(ab>2 fragments cleavage of both, the sequence-specific 
anti-SAAi peptide IgGs and a non-immune rabbit IgG fraction was 
performed by enzymatic digestion with pepsin [23]. The F(ab)2 frag-
ments were then purified by gel permeations chromatography to en-
sure the absence of residual IgG or Fc fragments. Both, intact anti-
SAAi peptide IgGs [22] and corresponding F(ab)2 fragments did im-
munochemically react with either SAA! or the corresponding peptide 
(40-63). 
2.3. Preparation of human monocytes and culture conditions 
The mononuclear cell fraction of buffy coats from healthy blood 
donors was obtained by Ficoll-Hypaque separation as described [24]. 
The mononuclear cell fraction was washed in phosphate buffered sal-
ine (pH 7.4, without Ca2+ and Mg2+), separated from platelets by 
overnight settlement at 4°C, and resuspended in RPMI 1640 medium 
supplemented with 5% heat-inactivated (56°C, 30 min) AB serum, 
penicillin (100 U/ml), streptomycin (100 (xg/ml), L-glutamine (2 
mM), pyruvate (2 mM), and HEPES buffer (50 mM). Mononuclear 
cells were seeded into 24-well culture plates (Falcon, Germany), and 
after 2 h of incubation at 37°C in a humidified 5% C0 2 , 95% air 
atmosphere, the non-adherent leukocytes were removed be several 
extensive washing procedures. Platelet-depleted monocyte cultures 
(5X 106/ml RPMI medium plus supplements without the addition of 
serum) were then incubated with different concentrations of SAAi or 
apo A-I (3.2 to 200 ug/ml) up to 12 h. Stimulation of cells was 
performed with calcium ionophore A23187 (final concentration: 0.5 
and 2.5 uM) up to 4 h in the presence/absence of the corresponding 
apolipoprotem or in the presence of a 10- to 20-fold molar excess of 
sequence-specific anti-SAAi peptide F(ab)2 or non-immune rabbit 
F(ab)2 fragments. At the end of the incubation the culture superna-
tants were removed, rendered cell-free by centrifugation (3500 rpm, 
4°C), and stored at —70°C until eicosanoid analysis. 
2.4. Quantification of cyclooxygenase metabolites 
After acidification to pH 3.2 and addition of 1802-labelled TXB2 
(prepared as described [25]), D4-PGF20!, and D4-PGE2, respectively, 
eicosanoids were extracted from cell supernatants with diethyl ether 
and separated by silicic acid column chromatography [26]. TXB2 (the 
stable hydrolysis product of TXA2), PGE2, and PGF2 a were analyzed 
as trimethyl silyl ether pentafluorobenzyl ester methoxime derivative 
by negative ion chemical ionization-gas chromatography/mass spec-
trometry chromatography (NICI-GC/MS) as described [27]. A Fumi-
gan gas Chromatograph 9619 coupled to a Finnigan 4500 mass spec-
trometer and an INCOS data system was used. Values for detection 
limits (5 to 20 pg of AA-metabolites measured by NICI-GC/MS) are 
based on a signal to noise ratio of 4:1. Interassay and intraassay 
coefficients of variations were 2.0 to 2.4 and 1.1 to 2.2%, respectively 
[26]. 
2.5. Electrophoresis, transfer to nitrocellulose and Co2*-binding 
properties 
SDS-PAGE under non-reducing or reducing conditions was per-
formed on 3.5-15% gradient slab gels at 180 V for 60 min using 
minigels (Bio-Rad) [23]. Analytical IEF was carried out as described 
previously [21]. Proteins were electrophoretically transferred to nitro-
cellulose membrane in 20 mM Tris-HCl (0.15 M glycine buffer, pH 
8.4) for 90 min at 200 mA. Detection of Ca2+-binding proteins/pep-
tides on nitrocellulose membranes after SDS-PAGE and IEF or dot 
blot experiments were performed by washing membranes in imidazole 
buffer (10 mM imidazole/HCl, 60 mM KC1, 5 mM MgCl2, pH 6.8) 
exactly as described [28]. Membranes were incubated in the same 
buffer containing 15-20 uCi 45Ca2+ (Du Pont NEN)/ml prior to auto-
radiography. 
3. Results 
As rSAA might induce calcium mobilization in resting hu-
man monocytes [14] we initially analyzed whether the addition 
of SAAi to resting and stimulated monocytes affects eicosa-
noid production. Coincubation of resting cells with SAAx 
(3.15 to 200 u,g/ml, 2-12 h) was without effects on secretion 
of TXB2, PGE2, and PGF2a- We therefore studied a possible 
involvement of SAAi during eicosanoid biosynthesis by 
stimulated cells. The major cyclooxygenase metabolite re-
leased from calcium ionophore-stimulated, platelet-depleted 
monocyte cultures after 4 h was TXB 2 (66.3 ± 28.2 ng/ 
5 X 1 0 5 cells, « = 1 2 ) . Analysis of prostaglandins secreted into 
the cell medium revealed 0.83 ± 0 . 5 n g / 5 X l 0 5 cells and 
CD 
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Fig. 1. Effects of SAAi on TXB2 production by A23is7-stimulated 
human monocytes. Adherent human monocytes (5X105 cells) were 
incubated with increasing SAAi concentrations and stimulated with 
2.5 uM calcium ionophore A23187 for 4 h in RPMI medium at 
37°C. The cell supernatant was then harvested on ice, centrifuged at 
3500 rpm and acidified to pH 3.2. After addition of stable isotope-
labelled internal standards (50 ng/ml) eicosanoids were extracted, 
separated by silicic acid chromatography and TXB2 was analyzed 
by NICI-GC/MS. Values represent mean ± S.D. of three experiments 
performed in triplicate determinations. 
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Fig. 2. Formation of cyclooxygenase metabolites by A23i87-stimulated monocytes in the presence of apolipoproteins. Adherent monocytes 
(5X 105/ml) were stimulated with either 2.5 uM (A, C, E) or 0.5 uM (B, D, F) calcium ionophore A23i87 U ) in the presence of 25 ug SAAi 
(•) or apo A-I (▼) at 37°C for the indicated time intervals. Quantification of TXB2 (A, B), PGE2 (C, D), and PGF2o (E, F) was performed 
by NICI-GC/MS. Values represent mean ± S.D. of four experiments performed in triplicate determinations, (o) refers to blank values, i.e. with-
out stimulation by A23i87. For more clarity S.D. values are shown only for eicosanoid secretion in the presence of SAAi and apo A-I. 
1.6 ±0.3 ng/5Xl05 cells for PGE2 and PGF2 a, respectively. 
When monocytes were stimulated by 2.5 uM A23i87 in the 
presence of SAAi (3.15 to 50 tig/ml) a dose-dependent for-
mation of TXB2 reaching levels from 60 ±29 (3.15 ug/ml) to 
110 ± 36 ng (50 (ig/ml) after 4 h was estimated (Fig. 1). Similar 
effects were observed at SAAi concentrations up to 200 ng/ml 
and when lower concentrations of A23i87 (0.5 itM) were used 
under the same assay conditions. In addition to TXB2, also 
PGE2 and PGF2 a concentrations were increased to a similar 
extent in A23i87-stimulated monocytes in the presence of SAAi 
(data not shown). SAAi concentrations higher than 200 ug/ml 
did not lead to a further increase of cyclooxygenase metabo-
lites released. 
In the next set of experiments the time-dependent formation 
of cyclooxygenase metabolites in the presence of either SAAi 
or apo A-I was investigated. From Fig. 2A it is evident that 
the formation of TXB2 in activated cells reached a plateau 
value 1 h after activation (25.5 ±9.6 ng/5xl0 5 cells, 2.5 uM 
A23i87)- Incubation of stimulated cells with SAAi led to a 
pronounced increase in TXB2 release in between 2- and 3-
fold (82.6 ±39.9 ng/5X 105 cells) after 4 h. To verify that the 
effect is specific for SAA, the same experiments were per-
formed with purified apo A-I (a negative acute-phase reactant 
[29]) present almost exclusively on native HDL. From Fig. 2A 
it is evident that apo A-I was without any effect on the for-
mation of TXB2 under these experimental conditions. Stimu-
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lation of monocytes with 0.5 uM A23i87 led to almost identical 
results as observed with 2.5 uM A23i87 (Fig. 2B). 
In addition to TXB2, we have also analyzed the time-de-
pendent formation of PGE2 (Fig. 2C and D) and PGF20! (Fig. 
2E and F) in A23187- (2.5 and 0.5 |xM) stimulated monocytes 
incubated in the presence of SAAi or apo A-I. Again, apo A-I 
was without effect on eicosanoid release, similar to data pre-
sented in Fig. 2A and B. PGE2 release was, however, stimu-
lated by SAAi (almost 3-fold, 0.6 vs. 1.6 ng/5Xl05 mono-
cytes) (Fig. 2C and D). Finally, also PGF201 secretion was 
enhanced in the presence of SAAi. While we have observed 
PGF2 a concentrations of about 1.5 ng/5xl0 5 in cells stimu-
lated with A23187 or A23i87 in the presence of apo A-I (Fig. 2E 
and F) PGF2 a concentrations secreted in the presence of 
SAAi were 3.0 ±0.4 ng/5Xl05 cells. It is noteworthy that 
the secretion of cyclooxygenase metabolites was very similar 
during experiments when cells were stimulated with either 0.5 
or 2.5 uM A23187 (compare Fig. 2A-F). 
We further addressed the question whether the tetrapeptide 
Gly48-Pro49-Gly50-Gly51 of human SAAX [19] might be the 
reason for enhanced formation of cyclooxygenase metabolites 
by activated monocytes. Therefore, A23i87-activated cells were 
coincubated with SAAi in the presence of F(ab)2 fragments 
(raised against position 40-63 of human SAAi) to block the 
proposed Ca2+ site in the molecule. Irrespective whether 
A23187- (0.5 or 2.5 uM) activated cells were incubated in the 
presence of SAAi and F(ab)2 fragments from either anti-
SAAi peptide IgGs or non-immune IgGs (as a negative con-
trol) TXB2 formation was nearly identical (Fig. 3). These data 
strongly suggest that the proposed Ca2+-binding region is 
either not exposed on the protein surface or not responsible 
for enhanced formation of cyclooxygenase metabolites in the 
presence of SAAi • 
To clarify whether isolated SAAi is able to bind Ca2+ (ei-
ther via the proposed Ca2+-binding domain or another non-
identified epitope) increasing SAAi concentrations were dot-
ted on nitrocellulose and incubated with 45Ca2+. It is evident 
from the autoradiograph (Fig. 4) that neither SAAi nor the 
corresponding peptide carrying the putative Ca2+-binding do-
main did bind 45Ca2+ even at highest protein/peptide concen-
trations used. As expected PLA2 effectively bound 45Ca2+ in a 
dose-dependent manner. The same results were obtained when 
purified SAAi or PLA2 (1 to 20 ug) were subjected to SDS-
1 p 
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Fig. 3. Synthesis of TXB2 by A23i87-stimulated monocytes in the 
presence of F(ab)2 fragments. 5X105 monocytes/ml were stimulated 
with 2.5 uM calcium ionophore A23187 in the presence of 50 jig 
SAAi (A). SAA was coincubated with either a 10-fold molar excess 
of rabbit anti-SAAi peptide (40-63) F(ab)2 (B) or non-immune rab-
bit F(ab)2 fragments (C). Values represent mean ± S.D. of three ex-
periments performed in duplicate determinations. TXB2 concentra-
tions in the presence of SAAi and A23187 are given as 100%. 
Fig. 4. 45Ca2+-binding properties by dotted proteins/peptide. PLA2, 
human SAAi, and synthetic peptide (corresponding to amino acid 
residues 40-63 of human SAA^ were dotted to nitrocellulose mem-
branes at the indicated concentrations and incubated with radioac-
tive Ca2+ as described in Section 2. Membrane bound ligands were 
visualized by autoradiography at —70°C. 
PAGE (under reducing or non-reducing conditions) or IEF 
and then electrophoretically transferred to nitrocellulose prior 
to incubating membranes with 45Ca2+. 
4. Discussion 
The presence of a-SAA mRNA in cells, e.g. endothelial 
cells, smooth muscle cells, and monocyte-derived macro-
phages [30,31], ultimately involved in the development of 
atherosclerosis, suggest a proinflammatory role of SAA in 
tissues. The major findings of the present study are that 
SAAi did not spontaneously induce eicosanoid secretion in 
resting monocytes. However, SAAi very efficiently enhanced 
biosynthesis of cyclooxygenase metabolites in stimulated 
monocytes up to 3-fold. Although a proposed Ca2+-binding 
epitope (Gly48-Pro49-Gly50-Gly51) is present on all SAA iso-
forms in mammals [2], we presented two lines of evidence that 
SAAi, the main representative of human acute-phase SAA, is 
not able to bind and/or transport Ca2+-ions. First, the use of 
sequence-specific antibodies raised against the proposed Ca2+-
binding domain of SAAi failed to impair formation of cyclo-
oxygenase metabolites; secondly, as demonstrated by autora-
diography, human SAAi is not able to bind Ca2+-ions. 
Previous investigations by Badolato and coworkers [14] re-
ported the rSAA (a protein homologous to the primary struc-
ture of human SAAi except for the addition of a methionine 
at the N-terminus) might induce Ca2+ mobilization in human 
monocytes. rSAA (at concentrations between 0.4 and 4 uM) 
caused an increase in cytoplasmic calcium concentrations in a 
dose-dependent manner similar to that when cells were acti-
vated by either FMLP or MCP-1, both chemoattractants. 
Findings that rSAA apparently does not induce Ca2+ mobi-
lization from intracellular stores but more likely stimulates 
influx of extracellular Ca2+ present in the medium have 
prompted us to investigate the combined effects of A23i87 
and SAAi on eicosanoid biosynthesis by monocytes. During 
the present study we have observed enhanced formation of 
cyclooxygenase metabolites by activated monocytes in the 
presence of SAAi concentrations similar to those mentioned 
in [14] and corresponding to in vivo concentrations about 50-
to 100-fold higher than baseline levels; levels reflecting acute-
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phase conditions in various inflammatory disorders which are 
observed particularly early after the onset of the inflammatory 
event. 
When occurring in vivo, enhanced TXA2 biosynthesis by 
activated monocytes must be considered a potent mediator 
of inflammation involved in the regulation of platelet-vessel 
wall interactions and in the regulation of blood vessel tone 
and hemostasis [18,32]. Observations that apo A-I does not 
exert proinflammatory properties under the same conditions 
described for SAAi (Fig. 2) could be seen in context of 
apo A-I as an antiatherogenic apolipoprotein [33]. The inhib-
itory effect of HDL, recently reported to block the chemo-
tactic effect of rSAA on monocytes in a dose-dependent man-
ner [13], is currently being examined. 
The mechanism of how SAAi may alter intracellular Ca2+ 
concentrations [14] and eicosanoid biosynthesis in further con-
sequence (Figs. 1 and 2) is presently not clear. It is important 
to note that the acute-phase response and activation of pro-
tein kinase C (PKC) in neutrophils and lymphocytes, cells 
involved in the inflammatory response, are concurrent events. 
In a previous paper [34] it was reported that SAAi but not 
apo A-I could serve as a substrate for PKC in vitro; maxi-
mum phosphorylation required the presence of Ca2+-ions. In 
addition, the inhibition of rSAA-induced chemotaxis of 
monocytes by staurosporine and H-7 seems to strengthen 
PKC-dependent mechanisms delivering chemotactic signals 
[14]. SAAi apparently induces calcium mobilization by acti-
vating a pertussis toxin-sensitive signalling pathway suggest-
ing that SAAi could bind to transmembrane G protein-
coupled cell surface receptors on monocytes. These receptors, 
however, appear to belong to a different class of chemotactic 
receptors known to bind RANTES, MIP-lcc, or MCP-1 [14]. 
If SAAi activates a receptor that impairs adenylate cyclase 
and prevents the rise in cAMP via an inhibitory G protein 
[14], one could speculate that the low cAMP concentrations in 
resting/activated cells would not induce monocyte function 
per se but more likely enhance signal generation via PLC 
or PLA2. From our studies we may hypothesize that SAA 
has an additive effect on calcium ionophore A23187, which 
can activate also membrane bound PKC [35]. However, iden-
tification of a possible SAA-receptor on monocytes will clarify 
the underlying mechanisms of enhanced eicosanoid biosynthe-
sis. As demonstrated by Walker and coworkers [36] the bind-
ing of intact HDL to a non-identified receptor on human 
fibroblasts very efficiently stimulated the activities of PLC 
and PLD, both enzymes involved in the intracellular signal-
ling cascade. 
In conclusion we have shown that SAAi, a proinflam-
matory apolipoprotein present on acute-phase HDL in vivo, 
is able to enhance the formation and secretion of TXA2, 
PGE2, and PGF 2 a from activated monocytes. However, en-
hanced biosynthesis and secretion of cyclooxygenase metabo-
lites mediating cell-cell interaction in vivo is not mediated via 
Ca2+-binding properties of SAAi but more likely the result of 
intracellular signalling pathways and requires further elucida-
tion. 
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